LifeSci Capital analyst Francois Brisebois initiated coverage of Savara (SVRA) with an Outperform rating and $11 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVRA:
- Savara’s MOLBREEVI: A Promising Solution for Autoimmune Pulmonary Alveolar Proteinosis with Blockbuster Potential
- Savara present results from Phase 3 IMPALA-2 Molgramostim study
- Savara management to meet virtually with Piper Sandler
- Savara Inc. Faces Legal Battle Over MOLBREEVI Controversy
- Savara price target raised to $11 from $8 at Guggenheim